Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.08, Briefing.com reports.
Shares of Genocea Biosciences (NASDAQ GNCA) traded down 6.4672% during trading on Thursday, hitting $3.8442. 131,047 shares of the stock were exchanged. The stock’s 50 day moving average price is $5.24 and its 200-day moving average price is $5.51. Genocea Biosciences has a one year low of $3.28 and a one year high of $7.29. The company’s market cap is $109.57 million.
In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $6.00, for a total value of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.70% of the company’s stock.
Several analysts have issued reports on GNCA shares. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a research note on Tuesday, May 16th. ValuEngine downgraded shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Cowen and Company reissued an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Monday, July 24th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $18.00 price objective (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $16.52.
WARNING: “Genocea Biosciences, Inc. (GNCA) Issues Quarterly Earnings Results” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2795562/genocea-biosciences-inc-nasdaqgnca-announces-quarterly-earnings-results-misses-estimates-by-0-04-eps.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.